Protein kinases are involved in the cardioprotective effects activated by platelet glycoprotein IIb/IIIa inhibitor tirofiban at reperfusion in rats in vivo-Reference-Cited by-同舟云学术

Protein kinases are involved in the cardioprotective effects activated by platelet glycoprotein IIb/IIIa inhibitor tirofiban at reperfusion in rats in vivo

Published:2018-08 Issue: Volume:832 Page:33-38
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Chang Shih-Tai,Yang Ya-Ting,Chu Chi-Ming,Pan Kuo-Li,Hsu Jen-Te,Hsiao Ju-Feng,Lin Yu-Sheng,Chung Chang-Min

Funder

Chang Gung Memorial Hospital

Publisher

Elsevier BV

Subject

Pharmacology

Reference34 articles.

1. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial;APEX AMI Investigators;JAMA,2007

2. Mechanisms involved in platelet procoagulant response;Bevers;Adv. Exp. Med. Biol.,1993

3. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials;Boersma;Lancet,2002

4. Invasive assessment of the coronary microcirculation in reperfused ST-segment-elevation myocardial infarction patients: where do we stand?;Bulluck;Circ. Cardiovasc. Interv.,2017

5. Platelet glycoprotein IIb/IIIa inhibitor tirofiban ameliorates cardiac reperfusion injury;Chang;Int. Heart J.,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intracoronary Versus Intravenous Low-Dose Tirofiban in Patients With ST-Elevation Myocardial Infarction: A Meta-Analysis of Randomised Controlled Trials;Heart, Lung and Circulation;2024-07

2. Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention;Coronary Artery Disease;2022-08-09

3. Platelets in Myocardial Ischemia/Reperfusion Injury;Hämostaseologie;2022-07-29

4. The pleiotropic effects of antithrombotic drugs in the metabolic–cardiovascular–neurodegenerative disease continuum: impact beyond reduced clotting;Clinical Science;2021-04

5. Activation of p38 MAPK participates in the sulbactam-induced cerebral ischemic tolerance mediated by glial glutamate transporter-1 upregulation in rats;Scientific Reports;2020-11-26